(S)-2-Amino-3-methyl-butyric acid 2-(2-amino-6-oxo-1,6-dihydro-purin-9-ylmethoxy)-ethyl ester

ID: ALA1349

Chembl Id: CHEMBL1349

Cas Number: 124832-26-4

PubChem CID: 135398742

Product Number: V125240

Max Phase: Approved

First Approval: 1995

Molecular Formula: C13H20N6O4

Molecular Weight: 324.34

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Valaciclovir | Valacv | Valacyclovir

Synonyms from Alternative Forms(10): Valaciclovir hydrochloride | Valacyclovir hydrochloride | Valaciclovir (as hydrochloride) | Valacyclovir hcl | 256-U-87 HYDROCHLORIDE | 256U87 HYDROCHLORIDE | BW-256 | BW-256U87 | NSC-759101 | Valtrex

Trade Names(2): Valtrex | Zelitrex

Canonical SMILES:  CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21

Standard InChI:  InChI=1S/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20)/t8-/m0/s1

Standard InChI Key:  HDOVUKNUBWVHOX-QMMMGPOBSA-N

Alternative Forms

1. Parent:

   

   ALA1349

   VALACYCLOVIR

2. Alternative Forms:

   

   ALA1349

   Valacyclovir Hydrochloride Hydrate

Molecule Features

Natural Product: Yes

Oral: Yes

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: Yes

Availability: Yes

Prodrug: Yes

Calculated Properties

Molecular Weight: 324.34

Molecular Weight (Monoisotopic): 324.1546

AlogP: -0.80

#Rotatable Bonds: 7

Polar Surface Area: 151.14

Molecular Species: NEUTRAL

HBA: 9

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 10

HBD (Lipinski): 5

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.99

CX Basic pKa: 7.48

CX LogP: -0.06

CX LogD: -0.40

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.44

Np Likeness Score: -0.28

References

1. Matsson P, Bergström CA, Nagahara N, Tavelin S, Norinder U, Artursson P..  (2005)  Exploring the role of different drug transport routes in permeability screening.,  48  (2): [PMID:15658873] [10.1021/jm049711o]

2. Song X, Vig BS, Lorenzi PL, Drach JC, Townsend LB, Amidon GL..  (2005)  Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter.,  48  (4): [PMID:15715497] [10.1021/jm049450i]

3. Shen W, Kim JS, Kish PE, Zhang J, Mitchell S, Gentry BG, Breitenbach JM, Drach JC, Hilfinger J..  (2009)  Design and synthesis of vidarabine prodrugs as antiviral agents.,  19  (3): [PMID:19097789] [10.1016/j.bmcl.2008.12.031]

4. Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P..  (2008)  Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,  51  (11): [PMID:18457386] [10.1021/jm7015683]

5. Garré B, Shebany K, Gryspeerdt A, Baert K, van der Meulen K, Nauwynck H, Deprez P, De Backer P, Croubels S..  (2007)  Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.,  51  (12): [PMID:17846132] [10.1128/aac.00116-07]

6. Sun J, Dahan A, Amidon GL..  (2010)  Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach.,  53  (2): [PMID:19957998] [10.1021/jm9011559]

7. Avdeef A, Tam KY..  (2010)  How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?,  53  (9): [PMID:20373811] [10.1021/jm901846t]

8. PubChem BioAssay data set, 

9. PubChem BioAssay data set, 

10. Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF..  (2004)  Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.,  1  (4): [PMID:16472241] [10.2174/1570163043334794]

11. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L..  (2010)  Membrane transporters in drug development.,  9  (3): [PMID:20190787] [10.1038/nrd3028]

12. Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A..  (2011)  QSAR-based permeability model for drug-like compounds.,  19  (8): [PMID:21458999] [10.1016/j.bmc.2011.03.011]

13. Massarelli I, Macchia M, Minutolo F, Prota G, Bianucci AM..  (2009)  QSAR models for predicting enzymatic hydrolysis of new chemical entities in 'soft-drug' design.,  17  (10): [PMID:19398207] [10.1016/j.bmc.2009.04.014]

14. Massarelli I, Macchia M, Minutolo F, Prota G, Bianucci AM..  (2009)  QSAR models for predicting enzymatic hydrolysis of new chemical entities in 'soft-drug' design.,  17  (10): [PMID:19398207] [10.1016/j.bmc.2009.04.014]

15. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, 

16. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W..  (2011)  Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).,  7  (12): [PMID:22194678] [10.1371/journal.pcbi.1002310]

17. Ganapathy ME, Huang W, Wang H, Ganapathy V, Leibach FH..  (1998)  Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2.,  246  (1): [PMID:9610386] [10.1006/bbrc.1998.8628]

18. Sawada K, Terada T, Saito H, Hashimoto Y, Inui KI..  (1999)  Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2.,  291  (1): [PMID:10525090]

19. Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, Sinko PJ..  (1998)  Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir.,  250  (1): [PMID:9753615] [10.1006/bbrc.1998.9298]

20. Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ..  (1999)  Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line.,  289  (1): [PMID:10087037]

21. Balimane P, Sinko P..  (2000)  Effect of ionization on the variable uptake of valacyclovir via the human intestinal peptide transporter (hPepT1) in CHO cells.,  21  (1): [PMID:11180195] [10.1002/1099-081x(200007)21:5<165::aid-bdd225>3.0.co;2-f]

22. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H..  (2002)  Human organic anion transporters and human organic cation transporters mediate renal antiviral transport.,  300  (1): [PMID:11861798] [10.1124/jpet.300.3.918]

23. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadée W, Amidon GL..  (1998)  5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.,  15  (1): [PMID:9706043] [10.1023/a:1011919319810]

24. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadée W, Amidon GL..  (1998)  5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.,  15  (1): [PMID:9706043] [10.1023/a:1011919319810]

25. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P..  (2012)  Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,  55  (10): [PMID:22541068] [10.1021/jm300212s]

26. Diez-Torrubia A, Cabrera S, de Castro S, García-Aparicio C, Mulder G, De Meester I, Camarasa MJ, Balzarini J, Velázquez S..  (2013)  Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme.,  70  [PMID:24185376] [10.1016/j.ejmech.2013.10.001]

27. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R..  (2004)  [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].,  28  (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2]

28. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

29. WHO Anatomical Therapeutic Chemical Classification, 

30. British National Formulary (72nd edition), 

31. DrugMatrix,  [10.6019/CHEMBL3885881]

32. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W..  (2016)  DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.,  21  (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015]

33. Unpublished dataset, 

34. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson.  (2020)  Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,  [10.1101/2020.04.21.054387]

35. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

36. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

37. Ellen Van Damme.  (2021)  Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity,  [10.6019/CHEMBL4651402]

38. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius.  (2021)  HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators,  [10.6019/CHEMBL4808148]

39. Birkmann A, Bonsmann S, Kropeit D, Pfaff T, Rangaraju M, Sumner M, Timmler B, Zimmermann H, Buschmann H, Ruebsamen-Schaeff H..  (2022)  Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections.,  65  (20.0): [PMID:36202389] [10.1021/acs.jmedchem.2c00668]

40. Wu YJ, Meanwell NA..  (2021)  Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.,  64  (14.0): [PMID:34213340] [10.1021/acs.jmedchem.1c00790]

41. Sutherland JJ, Yonchev D, Fekete A, Urban L..  (2023)  A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.,  14  (1): [PMID:37468498] [10.1038/s41467-023-40064-9]

Source

Source(11):

• Scientific Literature
• PubChem BioAssays
• Clinical Candidates
• DrugMatrix
• TP-search Transporter Database
• AstraZeneca Deposited Data
• WHO Anatomical Therapeutic Chemical Classification
• British National Formulary
• SARS-CoV-2 Screening Data 2020-21
• IMI-CARE SARS-CoV-2 Data
• Fraunhofer HDAC6